|1.||Jain, Kishor S: 1 article (11/2008)|
|2.||Manvar, Atul T: 1 article (11/2008)|
|3.||Bariwal, Jitender B: 1 article (11/2008)|
|4.||Shah, Anamik K: 1 article (11/2008)|
|5.||Singh, Jyoti S: 1 article (11/2008)|
|6.||Upadhyay, Kuldip D: 1 article (11/2008)|
|7.||Trivedi, Jalpa C: 1 article (11/2008)|
|1.||Hypertension (High Blood Pressure)
07/01/1990 - "It is concluded that TA 3090 is a safe and effective treatment for mild to moderate hypertension."
04/01/1992 - "Clentiazem (TA-3090, CAS 96125-53-0), a new benzothiazepine Ca++ antagonist, was orally administered to inpatients with essential hypertension at a dose of 30 mg at 8:00 a.m. "
04/01/1992 - "Analysis of the daily variation in blood pressure and pharmacokinetics after single or repeated administration of clentiazem to patients with essential hypertension."
01/01/1991 - "Efficacy and safety of clentiazem in patients with essential hypertension: results of an early pilot test."
04/01/1988 - "Development of hypertension in young SHR was significantly suppressed by chronic treatment with TA-3090 at a daily dose of 10 mg/kg p.o. "
10/01/1992 - "As patients with ischaemic disorders often present some degree of heart failure, the aim of this study was to investigate the effect of congestive heart failure on clentiazem (200 micrograms kg-1, i.v. bolus) pharmacokinetics in a canine model. "
03/01/1997 - "Therefore, our objective was to assess coronary and cardiac sensitivity to clentiazem in an experimental model of chronic heart failure (cardiomyopathic hamster, UM-X7.1, > 200 day old). "
10/01/1992 - "It is concluded that, in our model, congestive heart failure significantly modifies clentiazem disposition. "
10/01/1992 - "Effect of congestive heart failure on clentiazem pharmacokinetics in a dog model."
03/01/1997 - "Although the mechanisms involved in the vascular desensitization to clentiazem are still unknown, our findings may provide an additional explanation for the variable efficacy of calcium antagonists in the treatment of heart failure."
03/01/1991 - "If hearts were subjected to a 30-minute period of no-flow ischemia, the addition of 0.5 microM TA-3090 to the perfusate before ischemia significantly improved reperfusion recovery of mechanical function. "
03/01/1991 - "The protective effects of TA-3090 were not observed if TA-3090 was added at the time of reperfusion and were not related to a depression of function before ischemia. "
08/01/1998 - "These results indicate that reduction of Ca2+ entry from the extracellular space to the myocyte, as reflected by negative inotropism during pretreatment, is required for clentiazem to protect myocardium in a model of global ischemia and reperfusion."
08/01/1998 - "In the clentiazem group, [Ca2+]i showed no significant changes during ischemia or reperfusion. "
08/01/1993 - "Therefore clentiazem, at reperfusion after a 90-min ischemia, increases myocardial salvage limiting postischemic injury and providing sustained reduction of infarct size in dogs with collateral blood flow."
04/01/1995 - "Clentiazem (1, 3, and 10 mg/kg/day) administered orally for 23 days after the development of stroke increased the avoidance rate in a dose-dependent manner. "
01/01/1994 - "These results suggest that clentiazem treatment in the acute and subacute phases of stroke is beneficial."
01/01/1994 - "After stroke-prone spontaneously hypertensive rats (SHRSP) received a salt-loaded diet to accelerate onset of stroke, the therapeutic effect of clentiazem, a benzothiazepine Ca antagonist, on neurologic and histologic disorders was examined. "
01/01/1994 - "Effect of clentiazem (TA-3090) with posttreatment on neurologic and histologic disorders of stroke-prone spontaneously hypertensive rats with history of stroke."
06/01/1992 - "The hypotensive effect and organ-protective action by clentiazem may be involved in its prophylactic action against stroke."
11/01/1991 - "Clentiazem protects against chronic cerebral vasospasm in rabbit basilar artery."
11/01/1991 - "Experiments were carried out in rabbits to determine whether clentiazem (8-chlorodiltiazem), a cerebrovascular-selective calcium channel blocker, administered 24 hours before subarachnoid hemorrhage influenced the subsequent cerebral vasospasm. "
11/01/1991 - "The vascular damage associated with chronic cerebral vasospasm is related to calcium entry into the smooth muscle and endothelial cells, and possibly sympathetic nerve terminals, through calcium channels sensitive to clentiazem, which suggests that clentiazem may be of value in the management of chronic cerebral vasospasm."
|2.||Calcium Channels (Calcium Channel)
|7.||maleic acid (maleate)
|8.||Nitric Oxide Synthase (NO Synthase)
|2.||Induced Heart Arrest (Cardioplegia)